Agenus News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.05.20	Ausblick: Agenus veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
11.03.20	Ausblick: Agenus gewährt Anlegern Blick in die Bücher (finanzen.net)
07.08.19	Ausblick: Agenus stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
07.05.19	Ausblick: Agenus vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
12.03.19	Ausblick: Agenus stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net)
18.01.19	6 Top Gainers In Healthcare Sector (BIOC, AGEN, LPCN...) (RTTNews)
21.12.18	AGEN Soars On GILD Deal, FENC Rolling Ahead, AIMT Gaining Steam (RTTNews)
20.12.18	Agenus Collaborates With Gilead On Immuno-Oncology Therapies; Stock Surges (RTTNews)
04.11.18	Ausblick: Agenus präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
22.08.18	CVM Gearing Up For Big Event, BLFS Full Of Life, CRON Abuzz, AXON Awaits Data (RTTNews)
20.06.18	Agenus to Webcast Annual Meeting of Stockholders (PR Newswire)
12.06.18	Agenus Discovery Enhances Activity of Cancer Fighting Antibodies; Findings Published in Cancer Cell (PR Newswire)
06.06.18	Agenus to Present at the Jefferies 2018 Global Healthcare Conference in New York, NY (PR Newswire)
04.06.18	Agenus Presents Clinical Responses of AGEN1884 (anti-CTLA-4) and AGEN2034 (anti-PD-1) at ASCO 2018 (PR Newswire)
17.05.18	Agenus to Present Clinical Data on Lead Programs at ASCO 2018 (PR Newswire)
07.05.18	Agenus to Present at Deutsche Bank's 43rd Annual Health Care Conference in Boston (PR Newswire)
07.05.18	Agenus Reports First Quarter 2018 Financial Results and Provides Corporate Update (PR Newswire)
03.05.18	Agenus to Report First Quarter 2018 Financial Results on May 7, 2018 and Host Conference Call and Webcast (PR Newswire)
01.05.18	AgenTus Therapeutics to Present on Novel TCR Platform and Progress at PEGS Summit in Boston, MA (PR Newswire)
11.04.18	Three Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2018 Annual Meeting (PR Newswire)
29.03.18	Agenus to Present at Healthcare Investor Conferences In April (PR Newswire)
15.03.18	Agenus Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update (PR Newswire)
07.03.18	Agenus to Report Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018 and Host Conference Call and Webcast (PR Newswire)
22.01.18	Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034) (PR Newswire)
22.01.18	Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners (PR Newswire)
08.01.18	Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners (PR Newswire)
04.01.18	Agenus' Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018 (PR Newswire)
03.01.18	Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings (PR Newswire)
15.11.17	Agenus Receives License Fee of $4 Million USD from Merck (PR Newswire)
09.11.17	Agenus To Present on Lead Antibody Programs AGEN1884 (CTLA-4) and AGEN2034 (PD-1) at SITC 2017 (PR Newswire)
08.11.17	Agenus to Present at the Jefferies Global Healthcare Conference in London (PR Newswire)
07.11.17	Agenus Reports Third Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
26.10.17	Agenus to Report Third Quarter 2017 Financial Results on November 7, 2017 and Host Conference Call and Webcast (PR Newswire)
26.10.17	It's A No For PTCT As Expected, SRPT Revises Outlook Higher, TSRO Gets FDA Nod (RTTNews)
25.10.17	Shingrix with QS-21 Stimulon® Receives Positive Recommendation from CDC's Advisory Committee on Immunization Practices as Preferred Vaccine for Prevention of Shingles (PR Newswire)
23.10.17	Bruno Lucidi Appointed Chief Executive Officer of AgenTus Therapeutics, The Cell Therapy Subsidiary of Agenus (PR Newswire)
23.10.17	Agenus creates New Cell Therapy subsidiary named AgenTus Therapeutics (PR Newswire)
21.10.17	FDA Approves GSK's Shingles Vaccine with Agenus' QS-21 Stimulon® Adjuvant (PR Newswire)
13.10.17	GSK's Shingrix Containing Agenus' QS-21 Stimulon® Adjuvant Receives Marketing Authorization from Health Canada (PR Newswire)
19.09.17	Agenus to Present at Two Healthcare Investor Conferences In September (PR Newswire)
13.09.17	GSK's Shingrix containing Agenus' QS-21 Stimulon® adjuvant receives Unanimous FDA Advisory Committee recommendation for approval (PR Newswire)
13.09.17	FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over (PR Newswire)
12.09.17	Biotech Stocks on Investors' Radar -- PDL BioPharma, Progenics Pharma, Agenus, and Aptose Biosciences (PR Newswire)
04.08.17	How These Biotech Stocks are Performing? -- Agenus, Aptose Biosciences, RXi Pharma, and Tenax Therapeutics (PR Newswire)
03.08.17	Agenus Reports Second Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
28.07.17	Gainers & Losers Of July 27: CAPR, ANIK, MMSI, AZN, TTPH, AGEN... (RTTNews)
27.07.17	Agenus to Report Second Quarter 2017 Financial Results on August 3, 2017; Conference Call to Follow (PR Newswire)
21.06.17	GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting (PR Newswire)
21.06.17	Positive Phase 3 for GSK's shingles vaccine Shingrix with Agenus' QS-21 Stimulon® immune adjuvant (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

10.04.24		Mittwochshandel in New York: NASDAQ Composite liegt zum Ende des Mittwochshandels im Minus
10.04.24		Mittwochshandel in New York: NASDAQ Composite fällt mittags zurück
09.04.24		Pluszeichen in New York: NASDAQ Composite verbucht zum Handelsstart Zuschläge
08.04.24		Börse New York in Grün: NASDAQ Composite verbucht zum Handelsende Zuschläge
08.04.24		Starker Wochentag in New York: Am Nachmittag Gewinne im NASDAQ Composite
08.04.24		Freundlicher Handel in New York: NASDAQ Composite am Montagmittag mit Gewinnen
08.04.24		Börse New York: NASDAQ Composite steigt zum Start
05.04.24		Freitagshandel in New York: NASDAQ Composite beginnt Handel in der Gewinnzone

10.04.24

Mittwochshandel in New York: NASDAQ Composite liegt zum Ende des Mittwochshandels im Minus

10.04.24

Mittwochshandel in New York: NASDAQ Composite fällt mittags zurück

09.04.24

Pluszeichen in New York: NASDAQ Composite verbucht zum Handelsstart Zuschläge

08.04.24

Börse New York in Grün: NASDAQ Composite verbucht zum Handelsende Zuschläge

08.04.24

Starker Wochentag in New York: Am Nachmittag Gewinne im NASDAQ Composite

08.04.24

Freundlicher Handel in New York: NASDAQ Composite am Montagmittag mit Gewinnen